FTO and neoplasm: The results suggest that co-delivery of TAA and FTO inhibitors to TIDCs is anticipated to trigger a robust anti-tumor immune response by enhancing m6A methylation, fostering DC maturation, and activating anti-tumor immunity following the thermal ablation of HCC, thereby assisting in the induction of ICB to inhibit distant tumor growth and metastasis.